Paltry professional reimbursement relative to high costs of required space, support staff time, and supplies has stymied radiation oncologists taking the lead in directing radiopharmaceutical oncology care (read: oral I-131, Ra-223, Lu-177 PSMA, etc) for their communities, leading this editorial to conclude any hospital offering these services should fairly subsidize physician contributions. | Amdur, Pract Radiat Oncol 2023
